Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy.
1. A new pyrrolidine derivative (levetiracetam), resembling piracetam, was given as antiepileptic concomitant drug to patients with chronic epilepsy. 2. In a single-blind add-on rising-dose study the cognitive side-effects were investigated twice after one week of administration. 3. The results did not show any significant changes in cognitive performances.
Neyens
L G
LG
Epilepsy centre, Heemstede, The Netherlands.
Alpherts
W C
WC
Aldenkamp
A P
AP
D000284:Administration, Oral; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects*; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000077287:Levetiracetam; D008297:Male; D008568:Memory / Q000187:drug effects; D008875:Middle Aged; D009483:Neuropsychological Tests; D010889:Piracetam / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D011930:Reaction Time / Q000187:drug effects
D000927:Anticonvulsants; D000077287:Levetiracetam; D010889:Piracetam